Hematologic Oncology | Specialty

Emerging Novel Agents in RRMM

February 25th 2021

Paul G. Richardson, MD, reviews early data presented at ASH 2020 on the use of CELMoDs as well as melflufen for the management of RRMM. 

Using PI-based Combinations in RRMM

February 25th 2021

Saad Z. Usmani, MD, leads the discussion on new and updated data for novel PI-based combinations in RRMM as seen in the CANDOR, IKEMA, and BOSTON trials.

Time-Limited Therapy Takes Center Stage in Frontline and Relapsed/Refractory CLL

February 24th 2021

Fixed-duration treatment that leads to deep treatment-free remissions has become the prioritized strategy for patients with chronic lymphocytic leukemia, made possible by agents such as venetoclax, umbralisib, and lisocabtagene maraleucel.

ADCs, Triplets, and Transplant Maintain Solid Roles in Multiple Myeloma Therapy

February 24th 2021

Natalie S. Callander, MD, discusses the intriguing approaches in both the frontline and relapsed/refractory settings, including trials with antibody-drug conjugates.

Novel Treatment Combinations in Chronic Lymphocytic Leukemia

February 24th 2021

Dr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.

The Future of Chronic Lymphocytic Leukemia Treatment

February 24th 2021

Dr Ghia discusses emerging treatment strategies, including some promising clinical trials in chronic lymphocytic leukemia.

Treatment Sequencing in Chronic Lymphocytic Leukemia

February 24th 2021

Experts provide an in-depth look at their approach in sequencing treatment in chronic lymphocytic leukemia.

Final GENUINE Data Support Addition of Ublituximab to BTK Inhibitors in Relapsed/Refractory, High-Risk CLL

February 23rd 2021

Feburary 23, 2021 — The addition of the anti-CD20 monoclonal antibody ublituximab to ibrutinib led to a statistically higher overall response rate over ibrutinib alone with acceptable safety in patients with relapsed/refractory, high-risk, chronic lymphocytic leukemia.

Schiller Talks TKIs, Treatment Discontinuation, and Transplant in CML

February 23rd 2021

Gary J. Schiller, MD, discusses data from the 2020 ASH Annual Meeting and Exposition and the role of transplant in chronic myeloid leukemia.

MCL: Emerging BTKi-Combination Approaches

February 23rd 2021

Emerging BTK Inhibitors in Mantle Cell Lymphoma

February 23rd 2021

FDA Grants Priority Review to Ruxolitinib for Chronic GVHD

February 22nd 2021

February 22, 2021 - The FDA has granted priority review to a supplemental new drug application for ruxolitinib for use in adult and pediatric patients aged 12 years and older with steroid-refractory chronic graft-versus-host disease.

Novel Targets and Biomarkers in AML

February 22nd 2021

IDH1/2-Mutated Treatment-Naïve AML

February 22nd 2021

R/R Follicular Lymphoma: Second-line Treatment Selection

February 22nd 2021

Factors that hematologist-oncologists need to consider when selecting second-line therapy for relapsed follicular lymphoma.

R/R Follicular Lymphoma: Patient Prognosis

February 22nd 2021

Insight regarding the prognosis for patients with follicular lymphoma who relapse and impact of treatment sequencing on this trajectory.

Reduced Vincristine/Dexamethasone Dosing Schedule Shows Impressive Outcomes, Improved QoL in Pediatric B-ALL

February 19th 2021

A reduced frequency of maintenance vincristine and dexamethasone led to a 5-year overall survival rate of 98.6% and improved quality of life in pediatric patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia.

ITP Armamentarium Expands With the Hope of Limiting Long-Term Steroid Exposure

February 19th 2021

Kanwarpal S. Kahlon, MD, discusses the nuances of approaching treatment in ITP, updated guidelines to inform treatment selection, and recent data presented during the 2020 ASH Annual Meeting and Exposition that have the potential to advance the field.

CAR T-Cell Therapy for R/R DLBCL

February 19th 2021

Novel Therapies for R/R DLBCL

February 19th 2021